Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001104659-19-061825
Filing Date
2019-11-12
Accepted
2019-11-08 20:21:40
Documents
45
Period of Report
2019-09-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q tm1919529d1_10q.htm 10-Q 668283
2 EXHIBIT 10.1 tm1919529d1_ex10-1.htm EX-10.1 27334
3 EXHIBIT 31.1 tm1919529d1_ex31-1.htm EX-31.1 12243
4 EXHIBIT 31.2 tm1919529d1_ex31-2.htm EX-31.2 11318
5 EXHIBIT 32.1 tm1919529d1_ex32-1.htm EX-32.1 4517
6 EXHIBIT 32.2 tm1919529d1_ex32-2.htm EX-32.2 4361
  Complete submission text file 0001104659-19-061825.txt   3225164

Data Files

Seq Description Document Type Size
7 XBRL INSTANCE DOCUMENT ckpt-20190930.xml EX-101.INS 642797
8 XBRL TAXONOMY EXTENSION SCHEMA ckpt-20190930.xsd EX-101.SCH 32526
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE ckpt-20190930_cal.xml EX-101.CAL 18366
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE ckpt-20190930_def.xml EX-101.DEF 127731
11 XBRL TAXONOMY EXTENSION LABEL LINKBASE ckpt-20190930_lab.xml EX-101.LAB 217226
12 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ckpt-20190930_pre.xml EX-101.PRE 204493
Mailing Address 2 GANSEVOORT STREET 9TH FLOOR NEW YORK NY 10014
Business Address 2 GANSEVOORT STREET 9TH FLOOR NEW YORK NY 10014 212-554-4366
Checkpoint Therapeutics, Inc. (Filer) CIK: 0001651407 (see all company filings)

EIN.: 472568632 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38128 | Film No.: 191205422
SIC: 2834 Pharmaceutical Preparations